Paragon 28, Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Albert DaCosta
- Full Time Employees
- 525
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 14445 Grasslands Drive Englewood CO United States of America 80112
- IPO Date
- Oct 15, 2021
- CIK
- 0001531978
- Website
- paragon28.com
- Similar Companies
- Business
- Paragon 28, Inc. Paragon 28, Inc. (FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic segment, develops, manufactures, and commercializes innovative surgical solutions including plating systems such as Gorilla Plating and forefoot/hindfoot plating, intramedullary nails, screws including Monster Screw System, custom bone wedges, joint implants like APEX 3D Total Ankle Replacement System, fixators, staples, soft tissue implants, orthobiologics, and precision guide instruments for fracture fixation, deformity correction including progressive collapsing foot deformity and Charcot foot, forefoot/ankle procedures, trauma, and total ankle replacement; the company targets foot and ankle surgeons and hospitals primarily in the United States with international distribution through a dedicated sales network, operating from its headquarters in Englewood, Colorado, where it was founded in 2010. In April 2025, Paragon 28, Inc. completed its acquisition by Zimmer Biomet Holdings, Inc. Zimmer Biomet Holdings, Inc., becoming a wholly-owned subsidiary in a cash transaction valued at approximately $1.1 billion equity plus a contingent value right potentially adding up to $1.00 per share based on fiscal 2026 revenue milestones; this strategic move expands Zimmer Biomet's foot and ankle portfolio, leverages Paragon 28's specialized sales force for enhanced U.S. and global growth in ambulatory surgery centers, and accelerates penetration in the high-single-digit growth $5 billion foot and ankle market, following Paragon 28's 2024 net revenue of approximately $256 million reflecting 18% year-over-year growth.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Paragon 28, Inc. (FNA) And Encourages Investors to Reach Out
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Paragon 28, Inc. (FNA) And Encourages Stockholders to Reach Out
Bronstein, Gewirtz & Grossman, LLC Is Investigating Paragon 28, Inc. (FNA) And Encourages Stockholders to Connect
Paragon 28, Inc. (FNA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC Encourages Paragon 28, Inc. (FNA) Shareholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC Is Investigating Paragon 28, Inc. (FNA) And Encourages Shareholders to Connect
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Paragon 28, Inc. (FNA) And Encourages Shareholders to Reach Out
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Paragon 28, Inc. (FNA) and Encourages Shareholders to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC Encourages Paragon 28, Inc. (FNA) Stockholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Paragon 28, Inc. (FNA) and Encourages Investors to Learn More About the Investigation
Paragon 28, Inc. (FNA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC Is Investigating Paragon 28, Inc. (FNA) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC Encourages Paragon 28, Inc. (FNA) Stockholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Paragon 28, Inc. (FNA) And Encourages Stockholders to Reach Out
Bronstein, Gewirtz & Grossman, LLC Is Investigating Paragon 28, Inc. (FNA) And Encourages Stockholders to Connect
Paragon 28, Inc. (FNA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Paragon 28, Inc. (FNA) and Encourages Stockholders to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC Encourages Paragon 28, Inc. (FNA) Investors to Inquire about Securities Investigation
Hip Implant Maker Zimmer Biomet Cuts Annual Profit Forecast On Paragon 28 Deal
Bronstein, Gewirtz & Grossman, LLC Encourages Paragon 28, Inc. (FNA) Shareholders to Inquire about Securities Investigation